Skip to main content
JW LIFESCIENCE CORPORATION logo

JW LIFESCIENCE CORPORATION — Investor Relations & Filings

Ticker · 234080 ISIN · KR7234080000 KO Manufacturing
Open in API
Filings indexed 191 across all filing types
Latest filing 2019-03-13 Proxy Solicitation & In…
Country KR South Korea
Listing KO 234080

About JW LIFESCIENCE CORPORATION

https://www.jw-lifescience.co.kr/lifesc…

JW LIFESCIENCE CORPORATION is a specialized manufacturer focused on the development and production of infusion solutions. The company's product portfolio includes a comprehensive range of intravenous (IV) fluids, from basic solutions to advanced nutrient infusions containing essential components such as amino acids, lipids, proteins, vitamins, and minerals. A key area of innovation is the development of high-value-added products, including multi-chambered infusion solutions. The company operates world-class manufacturing facilities and maintains dedicated research and development centers to support its commitment to producing high-quality medical fluids for patient treatment.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for JW Life Science. It contains the agenda for the meeting, including financial statement approval, director appointments, and remuneration limits. It provides detailed information for shareholders to exercise their voting rights, including electronic voting instructions. This document is a formal proxy statement/information circular sent to shareholders to solicit votes for the upcoming AGM, which fits the definition of a Proxy Solicitation & Information Statement (PSI).
2019-03-13 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Proxy Solicitation' (위임장 권유) filed by JW Life Science (JW생명과학) for its 25th Annual General Meeting. It contains the agenda items for the meeting, including the approval of financial statements, amendments to the articles of incorporation, election of directors, and approval of remuneration limits for directors and auditors. This document is designed to provide shareholders with the necessary information to vote or grant a proxy, which fits the definition of a Proxy Solicitation & Information Statement (PSI).
2019-03-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large Shareholdings' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details changes in share ownership, including the identity of the reporter (SK Securities), the issuer (JW Life Science), and the nature of the transactions (share sales, stock splits, and bond conversions). This type of document is a mandatory disclosure to financial regulators regarding significant ownership thresholds and does not fit into the other specific categories like Annual Reports or Earnings Releases. Therefore, it is classified as a Major Shareholding Notification.
2019-02-25 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for JW Life Science. It details the meeting date, location, agenda items (such as financial statement approval, director appointments, and remuneration limits), and information regarding electronic voting. This document serves as the official proxy solicitation and meeting notice sent to shareholders to inform them of the meeting and request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2019-02-12 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from JW Life Science regarding the decision to pay a cash dividend. It specifies the dividend amount per share, the dividend yield, the total dividend amount, the record date, and the date of the board resolution. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2019-02-12 Korean
매출액또는손익구조30%(대규모법인15%)미만변경(자율공시)
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (JW Life Science) announcing preliminary financial results (sales and profit structure changes). It explicitly states that these are 'provisional' (잠정) figures that have not yet been audited or approved by the general meeting of shareholders. This type of disclosure is a standard 'Earnings Release' (ER) in the Korean market, providing key financial highlights before the final audited annual report is published. FY 2018
2019-02-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.